PAI
CRSP icon

Palo Alto Investors’s CRISPR Therapeutics CRSP Stock Holding History

Palo Alto Investors’s Portfolio CRSP Stock Details CRSP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.16M Hold
39,605
– – 0.3% 37
2026
Q1 		$1.88M Sell
39,605
-1,621
-4% -$85.5K 0.29% 38
2025
Q4 		$2.16M Hold
41,226
– – 0.3% 36
2025
Q3 		$2.67M Sell
41,226
-3,399
-8% -$195K 0.49% 29
2025
Q2 		$2.17M Buy
+44,625
New +$1.73M 0.46% 28

Other funds holding CRSP

AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
OAG
Orbis Allan Gray Hamilton, Bermuda $29.1B AUM 60.8% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
GP
GSK plc London $602M AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $1.04B AUM 262.99% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Palo Alto Investors's CRSP Position: Q2 2026 in Review

Palo Alto Investors held its CRISPR Therapeutics (CRSP) position steady in Q2 2026 at 39,605 shares worth $2.16M. The position accounts for 0.3% of the portfolio, ranked #37.

Palo Alto Investors first reported a position in CRSP in Q2 2025 and has held it in 5 quarters since. The position peaked at $2.67M in Q3 2025. 524 funds tracked by Wall St. Rank hold CRSP as of Q2 2026.

  • Palo Alto Investors held 39,605 shares of CRISPR Therapeutics worth $2.16M as of Q2 2026.
  • Palo Alto Investors left its CRISPR Therapeutics share count unchanged in Q2 2026.
  • CRISPR Therapeutics made up 0.3% of Palo Alto Investors's portfolio in Q2 2026, its #37 holding.
  • Palo Alto Investors first reported a position in CRISPR Therapeutics in Q2 2025 and has held it in 5 quarters since.
  • Palo Alto Investors's CRISPR Therapeutics position peaked at $2.67M in Q3 2025.
  • 524 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q2 2026.

Based on Palo Alto Investors's 13F filing for Q2 2026, filed 17 Aug 2026.